Health
CSOFT’s health blog aims to provide insight into complex diseases, treatment options and regulatory developments, and other prevalent health issues people face today.
FDA Grants Fast Track Designation to Syndax Pharmaceuticals
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Syndax Pharmaceuticals for the treatment of relapsed/refractory acute leukemia with either MLLr or NPM1 mutations called SNDX-5613. Previously, SNDX-5613 was granted Orphan Drug...
PMDA Grants Regulatory Approval for Leukemia Drug Therapy
Japan's regulatory body, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), has granted HUYABIO International, Shenzhen Chipscreen Biosciences' licensing partner, regulatory approval for leukemia drug therapy, Tucidinostat. Tucidinostat, also referred to...
LATAM Series: Argentina’s Medical Device Regulatory Pathway
In our last Latin American series blog post, we introduced the diversity and complexity of the life science market in the region, with specific focus on Brazil’s regulatory body and track for medical devices. This week, continuing with our Latin American series, we...
NMPA Grants First Approval to CAR T-Cell Therapy
The National Medical Products Administration (NMPA) has approved the first CAR T-cell therapy called Yescarta for China, which has been found to be successful in treating certain kinds of late-stage blood cancer. Fosun Pharma Kite Biotechnology will market Yescarta in...
FDA Accepts Fennec Pharmaceutical’s NDA Resubmission for PEDMARK™
Following up on their NDA resubmission, Fennec Pharmaceuticals has been granted U.S. Food and Drug Administration (FDA) approval for its unique formulation of sodium thiosulfate called PEDMARK™. PEDMARK™ is meant to prevent ototoxicity in patients between one month...
Parkinson’s Phase II Clinical Trial Authorized by FDA
The U.S. Food and Drug Administration (FDA) has authorized the Hope Biosciences Stem Cell Research Foundation (HBSCRF) to conduct Phase II clinical trial for simultaneous allogeneic adipose-derived mesenchymal stem cells administered intravenously to treat Parkinson's...
Roche COVID-19 Molecular Test Granted EUA for PCR Testing
The U.S. Food and Drug Administration (FDA) has granted Roche Emergency Use Authorization (EUA) for its PCR cobas® SARS-CoV-2 Nucleic acid test. The EUA was granted for use on the cobas® Liat® System, and is the first RT-PCR (reverse transcriptase polymerase chain...
FDA Grants Breakthrough Therapy Designation to Novartis’ Prostate Cancer Drug Therapy
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Novartis' prostate cancer drug therapy that is currently in Phase III development. The experimental treatment, called Lu-PSMA-617, has illustrated substantial improvements over...
“Significant Milestones” Reached on Various Regulatory Guidelines Reports ICH
The International Council for Harmonisation (ICH) has reported that "significant milestones" have been reached over the past year. From the adoption of guidances regarding carcinogenicity testing, residual solvent testing, and specifications for electronic Common...
EU Adds Another Blood Condition Side Effect to AstraZeneca’s COVID-19 Vaccine
The European Medicines Agency (EMA) has added another blood condition side effect to the growing list for AstraZeneca's COVID-19 vaccine. The rare blood condition known as capillary leak syndrome causes blood to spill from blood vessels to nearby muscles and body...
Categories
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com